The entire benefit of the 6,500-patient Corlanor study came from a reduction in hospitalization. "FDA Approves Amgen's Heart-Failure Drug Corlanor -- Update," at 6:10 p.m. EDT, misstated the benefits in the fifth paragraph.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amgen Charts.